Submit a Comment

ASH 2010 Annual Meeting: Immediate Impact on Current Clinical Practices T-cell Lymphomas

As a continuation of the collaboration between OBR and MDoutlook, we will be presenting you with a series of detailed post-ASH and post-SABCS trends research into the immediate clinical impact and integration of research presented at both meetings. The trends research is based on a series of Quick Polls across the MDoutlook platform of 47,000 cancer treaters globally. Feedback was collected within one week of each meeting and from more than 500 cancer treaters (approx 40% of respondents were attendees). No financial incentives were provided to participants.

This report covers T-cell Lymphomas.

Expanded Use of Romidepsin into Peripheral T-cell Lymphoma (PTCL) Will Have an Important Impact on Clinical Practice

Key Conclusions

  • Just over half of oncologists rated Abstract 114 High or Very High
    • Only 2% rated it Low
  • Suggests most will consider using romidepsin in PTCL when appropriate
    • Dependent on clinical suitability of patient AND regulatory approval / availability

 Abstract Title

  • Abstract 114: “Final Results From a Pivotal, Multicenter, International, Open-Label, Phase 2 Study of Romidepsin In Progressive or Relapsed Peripheral T-Cell Lymphoma (PTCL) Following Prior Systemic Therapy”

When Available and Used, Romidepsin is Only Used in a Limited Number of Patients with Cutaneous T-cell Lymphoma (CTCL)

 

Key Conclusions

  • Even with access to it, most oncologists have either used romidepsin in no or very few patients with CTCL
  • Low number may reflect rarity of this lymphoma

 Additional Information

  • “Not Available to me” is based on all responses; percentages for number of patients based only on those for whom it is available

Expanded Use of Pralatrexate into Cutaneous T-cell Lymphoma (CTCL) Will Have an Important Impact on Clinical Practice

Key Conclusions

  • About half of oncologists rated Abstracts on the use of pralatrexate in CTCL as High or Very High
    • Only 3% rated it Low
  • Suggests most will consider using pralatrexate in CTCL when appropriate
    • Dependent on clinical suitability of patient AND regulatory approval / availability

Abstract Titles

  • Abstract 1762: “Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF)”
  • Abstract 2800: “Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study”

Pralatrexate is Commonly Used in the Treatment of Peripheral T-cell Lymphoma (PTCL) When Available

Key Conclusions

  • Most oncologists with access to pralatrexate have used it in a limited number of their PTCL patients
  • Low numbers may reflect rarity of this lymphoma

Additional Information

  • “Not Available to me” is based on all responses; Percentages for # of patients based only on those for whom it is available

When Available and Used, Romidepsin is Only Used in a Limited Number of Patients with Cutaneous T-cell Lymphoma (CTCL)

Key Conclusions

  • Good awareness about these new therapeutics for T-cell lymphomas
    • High level of awareness may reflect the limited availability of highly effective treatments for these diseases
  • Most likely that these additional agents will be used in specific patient populations
    • May reflect the diversity of the T-cell lymphomas

Additional Information

  • Respondents indicated the type and extent each drug would impact the treatment landscape (or if unaware of the drug) in T-cell lymphomas
    • May have different impacts in other therapeutic areas

Conclusions from the ASH 2010 Quick Poll on T-cell Lymphomas

  • Presentations on the use of romidepsin in PTCL and pralatrexate in CTCL are seen as having a high clinical impact
  • Where available, both romidepsin and pralatrexate are being widely used by oncologists in T-cell lymphomas for which they already have FDA approval, albeit in a low number of patients
    • Romidepsin is currently approved for CTCL
    • Pralatrexate is currently approved for PTCL
  • Low numbers may reflect rarity of these lymphomas
  • Oncologists report they decide on the use of a drug for a particular tumor type independently of its use in other tumor types
  • With those it has an importance, drives increased use of 1st indication
  • While new drugs for T-cell lymphomas discussed at ASH are fairly widely known, they are expected to impact only a subset of patients

Final Thoughts

Quick polls are a fast way of measuring expected acceptance of clinical data post major medical meetings, and perhaps can be used to make some assumptions about adoption amongst providers. In today’s information hungry environment, the speed at which these polls can be conducted and analyzed can be advantageous for market planning and “pressure testing” acceptance of data amongst key stakeholders.

Submitted by Jan Heybroek, President, The Arcas Group

Email Jan Heybroek

You must be logged in to post a comment